Novartis opened the busy pharma earnings week with a second quarter that topped Wall Street on the line that matters most to the sell-side, core operating income. The group posted $5.9 billion in core operating profit, comfortably above the roughly $5.3 billion analysts had penciled in, while net sales returned to growth at $14.4 billion. The beat leaned almost entirely on a handful of newer oncology and immunology drugs that are still ramping hard. Yet the headline flatters a more mixed picture underneath, with the core margin slipping and statutory earnings down double digits. Management reaffirmed full-year guidance rather than raising it, a tell that the second half carries known headwinds. For investors, the question is whether the growth engines outrun the patent cliff now forming on the group’s biggest legacy drug.
The Read
- Core operating income came in at $5.9B, ahead of the ~$5.3B consensus, on net sales of $14.4B.
- Kisqali, Scemblix and Pluvicto drove the beat, but the core margin slipped to 41.2%.
- Full-year guidance was reaffirmed, not raised, with the Entresto patent cliff looming from November.
Sales Return to Growth While the Margin Slips
The top line did the job. Novartis reported net sales of $14.4 billion, up 3% in dollars and 1% at constant currency, enough to end a soft patch and return the group to growth. The core number was the standout, with core operating income of $5.9 billion landing above the Street’s roughly $5.3 billion estimate.
Profitability is where the story splits. The core operating margin came in at 41.2%, down 70 basis points at constant currency, as pricing pressure and mix ate into the sales gain. So the beat is a volume-and-mix story on newer drugs, not an efficiency story.
The two earnings lines tell opposite tales. Core EPS held flat at $2.41, in line with the stable operating base, while statutory EPS fell 17% to $1.71 on one-off items below the core line. CEO Vas Narasimhan framed it as a solid quarter that returned the group to sales growth with meaningful pipeline progress.
That framing is the same investor tension seen across this earnings season, where a clean top-line beat still leaves the market unconvinced. It echoed the reaction when Netflix stock dropped despite an earnings beat on cautious guidance.
Kisqali and Scemblix Carry the Beat
The growth is narrow and concentrated, which is exactly what the bull case wants. Breast-cancer drug Kisqali grew 43% to $1.695 billion, the single largest contributor, while multiple-sclerosis therapy Kesimpta rose 32% to $1.424 billion. Those two alone did the heavy lifting on the quarter.
The younger launches ramped even faster in percentage terms. Leukemia drug Scemblix jumped 89% to $562 million, radioligand therapy Pluvicto climbed 43% to $651 million, and cholesterol treatment Leqvio added 59%. These are the products that define the group’s next three years.
Now the mechanics matter for the read-through. When growth is this concentrated, the market pays for durability of the leaders and visibility on the next launches, not for a single quarter, much as it treated the record Q2 profit at TSMC as backward-looking versus its forward capex signal. Narasimhan pointed to continued pipeline momentum as the bridge past the coming patent losses.
Oncology Momentum Can Reprice the Multiple Higher
The bull case is straightforward. If Kisqali, Pluvicto and Scemblix keep compounding at anywhere near their current rate, they refill the revenue base faster than legacy drugs drain it, and the reaffirmed guidance starts to look conservative. A beat that management refuses to extrapolate is often the setup for later upgrades.
There is a defensive-quality angle too. In a tape rattled by AI-cycle volatility and Middle East risk, a Novartis delivering 3% sales growth and a 41.2% core margin is the kind of low-beta compounder that systematic money rotates into when it de-risks. The reaffirmed full-year outlook gives that money a floor to lean on.
The setup also rhymes with other defensives that quietly raised the bar this season. It was the same signal the market rewarded when Sodexo lifted its 2026 guidance on a Q3 beat, a reminder that steady European names can still surprise to the upside.
The Entresto Patent Cliff Is the Real Overhang
The bear case has a name, and it is Entresto. The heart-failure blockbuster made up 14% of total net sales last year and begins losing patent exclusivity in Europe from November. Generic competition on a drug that size does not dent the model, it reprices it.
This is why Novartis reaffirmed guidance rather than raising it. Management already flagged full-year core operating income to decline low single-digit even as net sales grow low single-digit, which tells you the margin pressure and Entresto erosion are baked into the second half. The 70 basis point margin slip this quarter is a preview, not a one-off.
The asymmetry investors have to price is real. On one side, a growth cohort compounding at 40% to 89%; on the other, a legacy franchise worth a seventh of sales rolling off patent into a declining-profit guide. The beat says the growth engines are working. It does not yet say they win the race against the cliff. That verdict comes with the ramp of the newer launches, which will move the shares far more than a single Q2 print.
More to come.
About the Author
